Foundry Partners, LLC Sage Therapeutics, Inc. Transaction History

Foundry Partners, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 30, 2023	SELL	$32.2 - $43.61 $118,367 - $160,310	-3,676 Reduced 7.23%	47,180 $1.8 Million
Q3 2022 Oct 21, 2022	BUY	$32.28 - $43.27 $266,761 - $357,583	8,264 Added 19.4%	50,856 $1.99 Million
Q2 2022 Jul 28, 2022	BUY	$27.52 - $37.99 $1.17 Million - $1.62 Million	42,592 New	42,592 $1.38 Million

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.